Digitally powered participant-directed studies. A Strategy for Decentralized Care. The Evolution of the Digital Patient Experience in Oncology & opportunities for Human Augmented Intelligence and Touch. Outlne: Precedent and example; Opportunities for Artificial Intelligence and/or Machine Learning? The human touch to augment technology; Challenges from a behavioral economics standpoint; Future directions. Digitally powered participant-directed studies are the
right direction and may be the new reality. Patient Symptoms During Their Cancer Journey. We must shift our focus to the ‘other’ 99% of time. Patient centricity unrestricted by provider encounters. Patient Generated Health Data. Evolving the Digital Patient Experience in Oncology. AI in Health & Medicine. TREATING THE WHOLE PERSON; Health coaching to address social determinants to: Solve the 4000-hour problem; Keep patients healthy at home; Close care gaps between clinic visits; Motivate healthy behavior changeto drive better outcomes. Digital Health Possibilities for Community-Based Support. Insights from a Pilot of Digital Health Coaching. Pilot Study Data. Outcomes of a Pilot Study Exploring the Role of Digital Health Coaching for Men with Prostate Cancer. Data, Healthcare and Technology...REMEMBER THAT THERE ARE SILOS INSIDE OF EACH OF THESE SILOS – THEY ARE THEMSELVES NOT MONOLITHS. EMPHASIS SHOULD BE THAT WE ARE NOT ONLY CREATING A BRIDGE TO OPEN COMMUNICATION.
WE ARE ALSO CREATING A NEW PERSON WHO HAS EXPERTISE IN ALL AREAS BROADLY – NOT ONLY JUST THESE 3.
ODF III - 3.15.16 - Day Two Morning SessionsMichael Kerr
Slide presentations delivered during morning sessions of Day Two of the California Statewide Health and Human Services Open DataFest - March 14 - 15, 2016, Sacramento, CA
Patient-Generated Data for Cancer Treatment and ManagementTommy Snitz
Research poster created by myself and Matthew Villarreal while we were students of The University of Texas at Austin's Health Informatics and Health IT Program.
Looks into the benefits and challenges of using patient-generated data in cancer treatment and management
Digital communications bring opportunity and risk to the therapeutic relationship. Doctors and other health professionals can learn to collaborate in person and online to protect informed decision making. Modified slightly from a talk August 8 2019 at Brigham & Women's Hospital/Dana-Farber Cancer Institute.
SAMSI Precision Medicine Keynote, August 2018: Data: where Precision Oncology...Warren Kibbe
The promise of precision medicine in oncology is predicated on the availability of accurate, high quality data from the clinic and the laboratory. Likewise, a Learning Health System is one in which we use data to monitor that we are following guidelines and care pathways to deliver the best care and not revert to prior practices (regression testing for care!) and also provide real world evidence to determine effectiveness and identify populations that would benefit from novel therapies. Into this mix of clinical drivers are the rapidly changing capabilities in instrumentation, computing, computation, and the pervasive use of sensors and smart devices. I will highlight a few of the obvious and perhaps not as obvious opportunities in leveraging the increasingly digital landscape in healthcare and biomedical research as we move toward a national learning health system for cancer.
ODF III - 3.15.16 - Day Two Morning SessionsMichael Kerr
Slide presentations delivered during morning sessions of Day Two of the California Statewide Health and Human Services Open DataFest - March 14 - 15, 2016, Sacramento, CA
Patient-Generated Data for Cancer Treatment and ManagementTommy Snitz
Research poster created by myself and Matthew Villarreal while we were students of The University of Texas at Austin's Health Informatics and Health IT Program.
Looks into the benefits and challenges of using patient-generated data in cancer treatment and management
Digital communications bring opportunity and risk to the therapeutic relationship. Doctors and other health professionals can learn to collaborate in person and online to protect informed decision making. Modified slightly from a talk August 8 2019 at Brigham & Women's Hospital/Dana-Farber Cancer Institute.
SAMSI Precision Medicine Keynote, August 2018: Data: where Precision Oncology...Warren Kibbe
The promise of precision medicine in oncology is predicated on the availability of accurate, high quality data from the clinic and the laboratory. Likewise, a Learning Health System is one in which we use data to monitor that we are following guidelines and care pathways to deliver the best care and not revert to prior practices (regression testing for care!) and also provide real world evidence to determine effectiveness and identify populations that would benefit from novel therapies. Into this mix of clinical drivers are the rapidly changing capabilities in instrumentation, computing, computation, and the pervasive use of sensors and smart devices. I will highlight a few of the obvious and perhaps not as obvious opportunities in leveraging the increasingly digital landscape in healthcare and biomedical research as we move toward a national learning health system for cancer.
RECOMMENDING AN EVIDENCE-BASED PRACTICE CHANGEWALDEN U.docxaudeleypearl
RECOMMENDING AN EVIDENCE-BASED PRACTICE CHANGE
WALDEN UNIVERSITY
JULY 28, 2019
Recommending an Evidence-Based Practice Change
My Facilityl is focused on providing quality healthcare to all patients regardless of their differences.
The facility is has a culture of embracing change as long as it helps in improving the patients’ health outcomes.
However, since our hospital is a community-based health service facility, there are some of things that need to be changed.
The healthcare facility offers cancer services including screening and management services. Screening is offered to the community occasionally when the facility organizes cancer awareness where they get more cancer professionals from other hospitals to help provide screening services to the people.
Recommending an Evidence-Based Practice Change
The problem facing the healthcare facility currently is the lack of cancer screening awareness among the community members and enough oncologists.
Cancer screening services require advanced technology and machines to ensure detection and diagnosis of cancer.
Cancer is one of the top diseases causing high mortality rates around the world presently.
The federal and national government are the key stakeholders who need to provide the hospitals with funds for purchase of cancer screening machines and hiring of enough oncologists.
The risk involved with this change is the cancer screening costs which might not be affordable to all people.
Organization Description and Readiness for Change
Recommending an Evidence-Based Practice Change
Increasing cancer screening awareness can be done in the community especially in various institution where many people come together.
Cancer screening awareness can also be increased by passing the information on importance of screening in social media and also for every patient that visits the hospital.
Cancer screening services should also be done freely to attract more people to go for screening services.
The facility can implement these changes by training all the nursing staffs and physicians on cancer screening information so they can pass the information to all the people they interact with and attend.
*
Recommending an Evidence-Based Practice Change
One of the measurable outcomes that can be achieved with the implementation of cancer screening awareness is the early detection of different types of cancers like colorectal, breast, cervical, prostate, among others (Alfa Scientific Designs, 2017).
The second outcome is the education on prevention strategies that people could adopt to help prevent cancer by educating the people on some of the cancer risk factors (Alfa Scientific Designs, 2017).
The awareness can also help in acknowledging the existence of screening services in the healthcare facility.
Knowledge of the early signs associated among the public could also be achieved through awareness campaigns.
Overall Quality Improvement in Processes: Continuous quality improvement initiat ...
Medical Informatics Update 2013 Programpaulgoldfarb
Event program for the Medical Informatics Update 2013 held October 16, 2013 and sponsored by the Center for Advanced Information Management at Columbia University and IBM Healthcare.
Andrew Roberts - Mobile Health Apps for Improved Patient Engagement and Educa...itnewsafrica
Andrew Roberts, Chief Information Officer at Clinix Health Group, on Mobile Health Apps for Improved Patient Engagement and Education, at Healthcare Innovation Summit Africa 2023 hosted by IT News Africa. #HISA2023 #Healthcare #Healthtech #HealthInnovation
Presented by Steve Mills, IBM Senior Vice President, Group Executive, Software & Systems Group
Learn more: http://www.ibm.com/software/products/en/category/health-social-programs
Are we ready for disruption in Translational Research through Digital Medicine?Ashish Atreja, MD, MPH
This is the slide deck that was presented at Translational Science 2016. Touches upon evidence generation as one of the most desired but expensive process in medical science. Provides examples of how Social Media, medical apps, quantified self movement are leading to patient generated data that can disrupt evidence generation process.
From personal health data to a personalized adviceWessel Kraaij
Invited talk at the health track of ICT.OPEN 2018, 20-3-2018
1. Related Data science challenges to Digital Health trends
2. Designing an infrastructure to support secure learning from distributed health data repositories, for personalized health advice
3. Supporting patients with rare diseases with patient driven research and the generation of new hypotheses based on patient experiences.
HEC 2016 Panel: Putting User-Generated Data in Action: Improving Interpretabi...Pei-Yun Sabrina Hsueh
Chair/Moderator: Pei-Yun Sabrina HSUEH, PhD (IBM T.J. Watson Research Center)
Panelists: XinXin ZHU, Bian YANG, Ying-Kuen CHEUNG , Thomas WETTER, and Sanjoy DEY
a IBM T.J. Watson Research Center, USA
b Norwegian University of Science and Technology, Norway
c Mailman School of Public health, Columbia University, USA
d, Department of Biomedical Informatics, University of Washington, USA
e Department of Medical Informatics, University of Heidelberg, Germany
The rise of consumer health awareness and the recent advent of personal health management tools (including mobile and health wearable devices) have contributed to another shift transforming the healthcare landscape. Despite the rise of health consumers, the impact of user-generated health data remains to be validated. In fact, many applications are hinged on the interpretability issues of this sort of data. The aim of this panel is two-fold. First, this panel aims to review the key dimensions in the interpretability, spanning from quality and reliability to information security and trust management. Secondly, since similar issues and methodologies have been proposed in different application areas ranging from clinical decision support to behavioral interventions and clinical trials, the panelists will also discuss both the success stories and the areas that fall short. The opportunities and barriers identified can then serve as guidelines or action items individuals can bring to their organizations to further improve the interpretability of user-generated data.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
More Related Content
Similar to Digitally powered participant-directed studies- Strategy for Decentralized Care. Adam Dicker, Jefferson Health, for mHealth Israel
RECOMMENDING AN EVIDENCE-BASED PRACTICE CHANGEWALDEN U.docxaudeleypearl
RECOMMENDING AN EVIDENCE-BASED PRACTICE CHANGE
WALDEN UNIVERSITY
JULY 28, 2019
Recommending an Evidence-Based Practice Change
My Facilityl is focused on providing quality healthcare to all patients regardless of their differences.
The facility is has a culture of embracing change as long as it helps in improving the patients’ health outcomes.
However, since our hospital is a community-based health service facility, there are some of things that need to be changed.
The healthcare facility offers cancer services including screening and management services. Screening is offered to the community occasionally when the facility organizes cancer awareness where they get more cancer professionals from other hospitals to help provide screening services to the people.
Recommending an Evidence-Based Practice Change
The problem facing the healthcare facility currently is the lack of cancer screening awareness among the community members and enough oncologists.
Cancer screening services require advanced technology and machines to ensure detection and diagnosis of cancer.
Cancer is one of the top diseases causing high mortality rates around the world presently.
The federal and national government are the key stakeholders who need to provide the hospitals with funds for purchase of cancer screening machines and hiring of enough oncologists.
The risk involved with this change is the cancer screening costs which might not be affordable to all people.
Organization Description and Readiness for Change
Recommending an Evidence-Based Practice Change
Increasing cancer screening awareness can be done in the community especially in various institution where many people come together.
Cancer screening awareness can also be increased by passing the information on importance of screening in social media and also for every patient that visits the hospital.
Cancer screening services should also be done freely to attract more people to go for screening services.
The facility can implement these changes by training all the nursing staffs and physicians on cancer screening information so they can pass the information to all the people they interact with and attend.
*
Recommending an Evidence-Based Practice Change
One of the measurable outcomes that can be achieved with the implementation of cancer screening awareness is the early detection of different types of cancers like colorectal, breast, cervical, prostate, among others (Alfa Scientific Designs, 2017).
The second outcome is the education on prevention strategies that people could adopt to help prevent cancer by educating the people on some of the cancer risk factors (Alfa Scientific Designs, 2017).
The awareness can also help in acknowledging the existence of screening services in the healthcare facility.
Knowledge of the early signs associated among the public could also be achieved through awareness campaigns.
Overall Quality Improvement in Processes: Continuous quality improvement initiat ...
Medical Informatics Update 2013 Programpaulgoldfarb
Event program for the Medical Informatics Update 2013 held October 16, 2013 and sponsored by the Center for Advanced Information Management at Columbia University and IBM Healthcare.
Andrew Roberts - Mobile Health Apps for Improved Patient Engagement and Educa...itnewsafrica
Andrew Roberts, Chief Information Officer at Clinix Health Group, on Mobile Health Apps for Improved Patient Engagement and Education, at Healthcare Innovation Summit Africa 2023 hosted by IT News Africa. #HISA2023 #Healthcare #Healthtech #HealthInnovation
Presented by Steve Mills, IBM Senior Vice President, Group Executive, Software & Systems Group
Learn more: http://www.ibm.com/software/products/en/category/health-social-programs
Are we ready for disruption in Translational Research through Digital Medicine?Ashish Atreja, MD, MPH
This is the slide deck that was presented at Translational Science 2016. Touches upon evidence generation as one of the most desired but expensive process in medical science. Provides examples of how Social Media, medical apps, quantified self movement are leading to patient generated data that can disrupt evidence generation process.
From personal health data to a personalized adviceWessel Kraaij
Invited talk at the health track of ICT.OPEN 2018, 20-3-2018
1. Related Data science challenges to Digital Health trends
2. Designing an infrastructure to support secure learning from distributed health data repositories, for personalized health advice
3. Supporting patients with rare diseases with patient driven research and the generation of new hypotheses based on patient experiences.
HEC 2016 Panel: Putting User-Generated Data in Action: Improving Interpretabi...Pei-Yun Sabrina Hsueh
Chair/Moderator: Pei-Yun Sabrina HSUEH, PhD (IBM T.J. Watson Research Center)
Panelists: XinXin ZHU, Bian YANG, Ying-Kuen CHEUNG , Thomas WETTER, and Sanjoy DEY
a IBM T.J. Watson Research Center, USA
b Norwegian University of Science and Technology, Norway
c Mailman School of Public health, Columbia University, USA
d, Department of Biomedical Informatics, University of Washington, USA
e Department of Medical Informatics, University of Heidelberg, Germany
The rise of consumer health awareness and the recent advent of personal health management tools (including mobile and health wearable devices) have contributed to another shift transforming the healthcare landscape. Despite the rise of health consumers, the impact of user-generated health data remains to be validated. In fact, many applications are hinged on the interpretability issues of this sort of data. The aim of this panel is two-fold. First, this panel aims to review the key dimensions in the interpretability, spanning from quality and reliability to information security and trust management. Secondly, since similar issues and methodologies have been proposed in different application areas ranging from clinical decision support to behavioral interventions and clinical trials, the panelists will also discuss both the success stories and the areas that fall short. The opportunities and barriers identified can then serve as guidelines or action items individuals can bring to their organizations to further improve the interpretability of user-generated data.
June 3, 2024 Anti-Semitism Letter Sent to MIT President Kornbluth and MIT Cor...Levi Shapiro
Letter from the Congress of the United States regarding Anti-Semitism sent June 3rd to MIT President Sally Kornbluth, MIT Corp Chair, Mark Gorenberg
Dear Dr. Kornbluth and Mr. Gorenberg,
The US House of Representatives is deeply concerned by ongoing and pervasive acts of antisemitic
harassment and intimidation at the Massachusetts Institute of Technology (MIT). Failing to act decisively to ensure a safe learning environment for all students would be a grave dereliction of your responsibilities as President of MIT and Chair of the MIT Corporation.
This Congress will not stand idly by and allow an environment hostile to Jewish students to persist. The House believes that your institution is in violation of Title VI of the Civil Rights Act, and the inability or
unwillingness to rectify this violation through action requires accountability.
Postsecondary education is a unique opportunity for students to learn and have their ideas and beliefs challenged. However, universities receiving hundreds of millions of federal funds annually have denied
students that opportunity and have been hijacked to become venues for the promotion of terrorism, antisemitic harassment and intimidation, unlawful encampments, and in some cases, assaults and riots.
The House of Representatives will not countenance the use of federal funds to indoctrinate students into hateful, antisemitic, anti-American supporters of terrorism. Investigations into campus antisemitism by the Committee on Education and the Workforce and the Committee on Ways and Means have been expanded into a Congress-wide probe across all relevant jurisdictions to address this national crisis. The undersigned Committees will conduct oversight into the use of federal funds at MIT and its learning environment under authorities granted to each Committee.
• The Committee on Education and the Workforce has been investigating your institution since December 7, 2023. The Committee has broad jurisdiction over postsecondary education, including its compliance with Title VI of the Civil Rights Act, campus safety concerns over disruptions to the learning environment, and the awarding of federal student aid under the Higher Education Act.
• The Committee on Oversight and Accountability is investigating the sources of funding and other support flowing to groups espousing pro-Hamas propaganda and engaged in antisemitic harassment and intimidation of students. The Committee on Oversight and Accountability is the principal oversight committee of the US House of Representatives and has broad authority to investigate “any matter” at “any time” under House Rule X.
• The Committee on Ways and Means has been investigating several universities since November 15, 2023, when the Committee held a hearing entitled From Ivory Towers to Dark Corners: Investigating the Nexus Between Antisemitism, Tax-Exempt Universities, and Terror Financing. The Committee followed the hearing with letters to those institutions on January 10, 202
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
mHealth Israel_Healthcare Finance and M&A- What Comes NextLevi Shapiro
Healthcare Finance and M&A, What Comes Next? Presentation by Matthew R. Kittay, National Co-Chair, M&A Practice Group, Fox Rothschild LLP. Includes fundraising and investments. Breakouts by subsector- Healthcare (overall), Healthcare services, Digital health, Biopharma, Pharmatech, Medtech, Healthcare IT. Healthcare transaction distribution breakouts. Exits remain flat. Avoiding common legal pitfalls like IP, compliance, governance structure. Current legislation in health law. IP strategy for healthtech.
Healthcare Market Overview, May 2024: Funding, Financing and M&A, from Oppenh...Levi Shapiro
Oppenheimer & Co. Inc, co-Head of Healthcare Investment Banking, Michael Margolis, provides H1 Healthcare Financing, Funding and M&A Overview. Table of Contents
1. Broader Market Overview
2. Biotech M&A Market Overview
3. Private Biotech Financing Market Update
4. Key Advice For Healthcare Companies
Current State of Play; Healthcare has Underperformed the Broader Market Over the Last Twelve Months; Signal-to-Noise is Getting Worse; Healthcare IPO Activity has Decreased Significantly Since 20–21 Pandemic Levels; Biotech Financing Activity Has Remained Robust in 2024; Biotech M&A Market Remains Incredibly Active; Biotech M&A Market Remains Incredibly Active; Big Pharma Upcoming Patent Expirations; Since November 2023 Oncology has accounted for over half of all M&A; Oncology, Autoimmune / I&I, and CV & Metabolic Remain the Top Areas in M&A; Small Molecule Beats Out All Other Modalities in M&A Despite IRA Concerns; Value of Big Pharma Acquisitions by Therapeutic Area in Q1 2024; Private Financing Market Update; 2024 Private Placement Activity On Track to Approach, If Not Exceed, 2020 Levels; Oncology, Particularly Solid Tumor, Continues to Attract VC Investors; Despite the IRA, Small Molecules Continue to Attract VC Dollars; Preclinical-Stage Companies Make Up Almost Half of Private Placements in 2023; Valuations by Development Stage – 2023; Typical Biotech Investors Remained Active in Q1 2024; 23 $100M+ Deals were Raised in Q1 2024; Biotech Fundraising Momentum Continued into 2024; Key Advice For Israeli Healthcare Companies; Although Israel has Strong Presence on US Public Markets, There is Room to Grow; Telling Your Story Effectively; Interacting with Investors to Build Long-term Credibility; Seven Simple Rules for Pitch Decks;
Version Bravo- The Springboard for Navy SEAL entrepreneurship, cohort 003Levi Shapiro
Description of the Version Bravo intensive entrepreneurial launch program for 7 Israeli and 7 US former Navy SEALs. Details about each startup concept, the CEOs, the sector, etc.
Radical Life Extension_Dr. Leon Peshkin_Dec 2023Levi Shapiro
Presentation for mHealth Israel by Dr. Leon Peshkin, Harvard Medical School, exploring research into Embryology and Longevity, emphasizing Germline and protein aggregates. Includes current overview, anti aging through history, Lifespan Expansion, ALEC: Animal Life Expectancy in Controls, Scalable Platform in Pharmacobiology, Embryos Cleanse Protein Aggregates, Lysosomal switch triggers proteostasis renewal, Xenopus, Rejuvenation Roadmap, Citizen Science Approach to Aging, Xenopus: Maternal Dowry Molecules, Human Disease Modeling
Israel’s Life Science Hub 2023 English Abstract.pdfLevi Shapiro
The war between Israel and Hamas brings its own set of business
challenges. Challenges that may impact how we communicate with
partners and investors abroad. We should portray the life science sector as resilient and adaptable, even in times of crisis. This document is a a messaging outline for Israel's Life Science Hub despite the war with Hamas. Four key points to emphasize:
1) Global activity (resilience and agility)
2) Continuity of care and preventive medicine
3) World leading clinical trials industry
4) Dynamic scientific, research and entrepreneurial ecosystems
Gil Bashe FINN Partners: The Future of Digital Health – Nose Dive or Transfor...Levi Shapiro
The Future of Digital Health – Nose Dive or Transformation, by Gil Bashe, Dec 4th, 2023 at the mHealth Israel conference. Digital Health Innovation Ecosystem Investment Trends. Data & Methodology. Digital Health Taxonomy. Key Insights for Digital Health Innovation in H1 2023. Global Digital Health Funding Across Regions. Funding in North America. Shifting Focus in North America Digital Health Funding. Investment Focus for Digital Health Venture Funding. Ventures are turning to partnerships for proof points, scale and funding. 2022 new partnerships. North America digital health investor participation. Most active partners in North America. North America Ecosystem Development. Venture distribution by stage. Funding distribution. Comparison to 2022 Funding. Noteworthy deals, noteworthy exits.
Urgent Request and Call for Action for Ensuring Safety and Inclusivity at MITLevi Shapiro
We, 465 MIT Alumni, Staff, and Students, are writing to express our deep concern, fear, and disappointment regarding the recent protest that took place Thursday afternoon, in front of the MIT Stratton Student Center. While we fully support the principles of free
speech and the right to peaceful assembly, it is essential that we also prioritize the safety and well-being of all members of the MIT
community.
During the protest, a particular slogan was prominently displayed and chanted, which has raised significant concerns. The slogan
"From the [Jordan] river to the [Mediterranean] sea, Palestine will be free!" has been a source of contention due to its potential
implications and the real safety risks it poses to Jewish and Israeli students on campus [See video footage attached]. This slogan
has been time and again associated with calls for the destruction of the State of Israel and has been used in contexts that
promote violence, which raises legitimate concerns about the safety and security of our Jewish and Israeli students and staff.
Furthermore, we would like to draw your attention to recent events that demonstrate the potential dangers associated with this
slogan. During the 2023 Israel-Hamas war, British Home Secretary Suella Braverman proposed criminalizing the use of the slogan
in certain contexts, recognizing the potential harm it can cause. Additionally, on October 11, ‘23, Vienna police banned a
demonstration, citing the inclusion of the phrase "from the river to the sea" in invitations, as it was seen as a portrayal of a violation
of Article 2 of the European Convention on Human Rights.
In addition to the use of these derogatory messages, several attendees of the event used hateful wordings and messages towards
Jewish and Israeli bystanders. In one case, a perpetrator aggressively held their bicycles as intended to harm a Jewish MIT student,
stating that “[your] ancestors did not die in the Holocaust so they could kill Palestinians” [See video footage attached]. In another
incident, protesters chanted “one solution, intifada revolution”. In the context of the on-going Israeli-Palestinian conflict, the word
"Intifada" means the armed and violent Palestinian insurrection targeting Israelis, including civilians, which resulted in the killing of
thousands of Israelis in the last few decades.
On Oct. 22nd, a statement by MIT CAA (Coalition Against Apartheid) came to our attention. In this document, MIT CCA states that
they "hold the Israeli regime responsible for all unfolding violence". They later call the October 7th terror attack a "response to
the settler colonial regime", and continue justifying it throughout the document.
In this matter, MIT CAA is justifying the heinous and barbaric crimes committed on Oct 7th. Furthermore, these statements have the
potential to fuel acts of aggression
Overview of the Israeli exhibitors at the 2023 HLTH conference in Las Vegas. Exhibitors included 6Degrees, AppScent, Belong.Life, Datos, Expecting, IntraPosition, Kahun Medical, Kemtai, Maverick, Neteera, QuantaIX, Respiration Scan, Nerivio, Xoltar.
40% of Israeli technology investment is devoted to Life Science. Within that domain, the largest sector is Medical Devices and Digital Health (over 65 percent of companies). In the medical device arena, Israeli scientists and engineers have integrated advanced technologies in electronics, communications and electro-optics to develop world-class innovations in Digital Imaging, Medical Lasers, Telemedicine, Early Diagnostics,
Smart Surgical Equipment and more. Over 600 medical device exporters engaged in a variety of medical application
such as Cardiovascular and Peripheral Vascular, Neurology and Degenerative Diseases, Preparedness and Emergency
Medicine, Intensive Care, Women Health, Orthopedics and Sport Medicine, Gastrointestinal, Infection Control, Ophthalmology, Pain and Wound Management, Oral and Dental Care, Dermatology and Aesthetics
Baptist Health- Engineering the Future of HealthcareLevi Shapiro
Presentation by Mark Coticchia, Chief Innovation Officer, Baptist Health, for mHealth Israel community, September, 2023. Baptist Health has internationally renowned centers of excellence in cancer, cardiovascular care, orthopedics and sports medicine, and neurosciences.
A not-for-profit organization supported by philanthropy and committed to its faith-based charitable mission of medical excellence, Recognized by Fortune as one of the 100 Best Companies to Work For in America and by Ethisphere as one of the World’s Most Ethical Companies.Innovation is paramount to health system’s performance and reputation.
Becker’s 2019 Advisory Board survey revealed innovation and technology ranked as the top priority among healthcare finance professionals - up from eighth in 2018. 90% healthcare/life science leaders agree that the pandemic will fundamentally change the way they do business, requiring new products, services, processes, and business models (McKinsey: Innovation Through Crisis Survey). Innovation has been proven to help health systems in many ways. A capability and culture of innovation accomplish numerous goals:
Innovation capability and culture improve the care and work environment. They enhance the reputation through recognition for discoveries made at and through Baptist Health. They aid in the recruitment and retention of top talent. And they help systems harness money that otherwise would be leaving the system – licensing revenues and investment returns and corporate research support and donor revenues. Successful Programs - Common Underpinnings. Innovation as a strategic, institutional priority
Program built on institutional assets and centers of excellence
Experienced, professional team
Technology development and sourcing, Dedicated, long term support. Doing healthcare innovation well at a large enterprise takes a highly specialized team and skill set. Collectively, they need to have deep knowledge of healthcare regulation, medical procedures, patient safety, business development, transactions, business law, innovation markets, entrepreneurship, venture capital, commercialization, tech transfer, organizational change management, and much more. Programs- services, technology management, corporate co-creation, global medical service lines and facilities; Focus on market opportunity vs. technology; Select & concentrate on winners; Operate as a business; Proactive in new company formation; Progress, milestones, preliminary results; Building New Innovation Pathways; Improving Treatment for Cancer Patients; Predicting & Preventing Heart Attacks; Improving Outcomes in Cardiac Care; Enhancing a Culture of Innovation at Baptist Health & South Florida; Cleerly, TriVentures, COTA; Innovation is paramount to health system’s performance and reputation.
Baptist Health has established an innovation function predicated on best practices and tailored to its assets and the opportunities extending from Miami’s economic growth
YEDA Techn Transfer at Weizmann Institute- Discord and Challenges in Academic...Levi Shapiro
Presentation by Yael Klionsky, YEDA, for the mHealth Israel community in September, 2023. Title: Challenges in Academic Technology Transfer. Examples-
Transplantation Immunology and Immunometabolism. Efranat Pharma was developing an anticancer immunotherapy treatment based on a natural plasma protein molecule. From target discovery to clinical validation. Clinical-stage drug discovery and development company utilizing a broadly applicable, predictive
computational discovery platforms to identify novel drug targets and new biological pathways and develop
therapeutics in the field of cancer immunotherapy. To allow SOCIETY to benefit from discoveries made at the academic institution. To enable SCIENTISTS to transfer their new technologies to the market. To create an additional source of INCOME for the INSTITUTE so that more independent research can be conducted. Three important elements that make an idea patentable:
1) The invention must be new: the same idea can’t have been
published before in any form; 2) There must be some inventive step of ‘non-obviousness’.
This can be hard to define and depends on the context; 3) The disclosure in a patent must be sufficient for a skilled
person to reproduce the invention with only routine effort; Technology Transfer Company - modus operandi; OUR PURPOSE- To provoke transformative scientific breakthroughs that will shape the future of humanity; SCIENTIFIC STAFF- 300 Principal investigators, >2,000 Research students and PhDs; 5 FACULTIES – BASIC SCIENCE, Biology, Physics, Biochemistry, Math/CS
Chemistry; Generated IP- 57% in Life Science & Biotech; Among the Highest
Income per Researcher
Worldwide; 1959 (First TTO outside the US); Today- More applications per PI than in most Ivy league universities; Copaxone- >$30B
ANNUAL SALES BASED ON Weizmann IP; 20 new licenses per year and 10 new companies per annum; www.yedarnd.com
HADASIT: Tech Transfer and More in Life ScienceLevi Shapiro
Overview of activities in Life Science of Hadasit, the technology transfer arm of Hadassah Hospital in Jerusalem. Includes details about Jerusalem Biodesign program; spinouts like Brainwatch; details about tech transfer (the Secret Engine Behind Israel’s Success); relationship and examples of TTOs enabling Israel's greatest success stories; contrasting of Adademia (Scientific driven research, Creation of new knowledge, Publication, Sharing of Material, Social responsibilities) and Industry (Applied research & specific objectives, Develop new products, Product development, Secrecy and patent protection, Organization responsibilities); Development gap between initial inventions and product development; the Art of translation (from academic research to medical companies); Tech transfer transforms cutting-edge research into marketable healthcare technologies; LICENSING TO EXISTING COMPANIES; SPINNING OFF STARTUPS; CO-DEVELOPMENT OF JOINT IP; Technology Transfer Offices from Academia/Research Hospitals – to Industry; Overview of Hadassah and Hadasit (TECHNOLOGY TRANSFER COMPANY AND INNOVATION ENGINE OF HADASSAH UNIVERSITY HOSPITALS); Examples of “HADASSAH MADE” PRODUCTS IN THE GLOBAL MARKET; RECENT TECH TRANSFER SUCCESS; Example- Lineage Exclusive Worldwide Collaboration with Genentech Opregen® RPE Cell Therapy for the Treatment of Ocular Disorders; HADASIT PILLARS-
NURTURING INTERNAL INNOVATION, Tech Transfer, EXTERNAL INNOVATION. External- SERVICES & COLLABORATIONS WITH COMPANIES, BIOHOUSE FOR STARTUPS, DIGITAL HEALTH ACCELERATOR); Internal Innovation- NURTURING INTERNAL INNOVATION, HADASSAH SEED FUND, JERUSALEM BIODESIGN PROGRAM; TYPES OF RELATIONS WITH EXTERNAL COMPANIES- CONSULTING, SAB, CLINICAL TRIALS, R&D SERVICES, DATA LICENCE, ALPHA/BETA SITE, PILOTS, DESIGN PARTNERSHIPS.
Presenting to Investors & the Media.pdfLevi Shapiro
Presenting to Investors and the Media, lecture by Drew Levinson, LifeSci Communications to mHealth Israel. Three sections: Making a good presentation, Handling
interviews with reporters and Answers that resonate. PRESENTING TO INVESTORS AND THE MEDIA- Compelling delivery, Commanding a room, • Lasting Impact. A good presentation includes Information, Motivation and Excitement. Never put them to sleep. Audience impact includes content, credibility and delivery. Decisions are made leading to potential partnerships, winning business, so much more than a deck, your business, your brand, you. How to captivate begins with storytelling and conversation. More than features- benefits, humanize, positive impact. Don't complicate your message with jargon. Feel the passion- contagious, vision, determination. Know your audience- who are they, what do they know about you, how much do they know, interests, concerns. Articulate your vision- see it, feel it, believe in it. Take them on your journey- compelling narrative, make it personal, why are you doing this, inspiration. Your team- experienced, knowledgeable, aligned, execute. Risks and challenges- recognize, address, plan to mitigate. Test drive your room. What does it look like? Where is the podium? Where will I be standing? Where will you be sitting? Feel comfortable. Three parts to attention. The beginning- attention, interest, what's in it for them, entusiasm, preview. The middle- core, insights, challenges, solutions, relatable. The ending- summary, reinforce, messages, benefits, call to action, keep the momentum going. How to answer questions. The Four R's: repeat, reinforce, refer, remember. Talking to reporters- necessity; Good interview can enhance reputation; Bad interview can tarnish reputation; Preparation is vital. Shapes public opinion: Elevates your brand; Establishes authority; Showcases your business; A bridge; Reputation; Trust; Visibility. Know the reporter. Audience; What have they written; Previous stories; Questions asked. Concise- clear, succinct, engaging. Make it relatable: Stories; Anecdotes; Experiences; Examples; Metaphors; Connect. Honesty and transparency. It is okay not to know every answer. You don’t have to answer every question. Control the narrative. What not to do when talking to reporters. Come up with another way to say no comment. What to wear- solid colors, blues and grays, nothing distracting. Expertise, passion, vision, lasting impression, connections. High stakes, high rewards. Preparation; Know your audience; Deliver with confidence; Enthusiasm; Authenticity. Begin the journey. Engage in dialogue; Build relationships; Inspire trust and confidence; Valued; Enlightened; Motivated and excited.
Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgic...Levi Shapiro
Presentation by Nissan Elimelech, Founder, Augmedics: How I Built the World's First XR Surgical Navigation Company and What's Next for XR. Covers the company founding across multiple milestones and key success factors.
Beyeonics CEO, Ron Schneider, Advances in Medical XRLevi Shapiro
Overview by Beyeonics CEO, Ron Schneider, about the company. Beyeonics One is the first ophthalmic exoscope with an augmented reality surgical headset. It is a high-definition, fully digital imaging platform enabling surgeons to see a magnified, three-dimensional (3D) image of the surgical field. The small footprint, the fast setup, automation, and zero turnover time between procedures all contribute to the efficiency operating rooms strive for. Over 3000 cases to date. Unconstrained Movement. Unconstrained workflow. Data connectivity. Designed for continuous innovation.
XRHealth is revolutionizing healthcare, bringing patient care into the Metaverse. Includes a description of the TeleHealth Platform. Lessons Learned – Building the clinical Metaverse. Last mile delivery
Building a product in the Metaverse is easy – getting people to use it is hard. Virtual Care can’t be based only on XR. HMDs bring friction – Charging, Guardian, Safety, Passwords etc. Expanding virtually in a brick & mortar payer environment. Once you cross the chasm – adherence/ satisfaction/retention goes ballistic. Patient Outcomes-
Patients report significant improvement in symptoms following treatment. Adherence - patients follow Home Exercise Plans as prescribed. 92.2% with XRHealth vs 50% with regular treatment. Patient satisfaction - 85 NPS vs 38 NPS in healthcare
93.3% patient retention -complete treatment cycle as prescribed. XRHealth Luna AI Reduces Hot Flashes and Improves Psychological Well-Being in Women with Breast and Ovarian Cancer: A Pilot Study. Virtual reality immersion compared to monitored anesthesia care for hand surgery: A randomized controlled trial. Lessons Learned – Autism Spectrum Disorder. The future of the Mediverse.
Digital Health in US Health Systems.pptxLevi Shapiro
April, 2023 presentation by Gil Bashe, Global Chair, Health Practice, FINN Partners. Insights and analytics, in collaboration with Galen Growth, tracking Digital Health collaboration, adoption, integration, and best practices across the leading US Health Systems. There is a section about focus areas for digital health in health systems and hospitals. The most active health systems are partnering more in diagnosis and have a higher share of digital tools for research. Comprehensive breakout of digital health activities at the Top 10 players: Mayo, Mount Sinai, Cleveland Clinic, Sloan Kettering, Massachusetts General, Northwell, Cedars Sinai, Brigham & Women's, InterMountain. Global breakout of health systems with digital health partnerships at scale. Geographical breakout of digital health partner headquarters (by region). Strong preference for B2B business model. 1/3 of digital health partnerships with Early Stage venture companies. Emphasis is on strong clinical evidence. Portfolio size allows greater diversity. Cluster distribution depends on therapeutic area. Digital health analytics breakout including alpha score, venture similarity score, venture valuation, team signal, partnership signal, evidence signal.
Course Syllabus (Digital Rosh): The Future of Digital Medicine- Biology, Gene...Levi Shapiro
Syllabus for the Future of Digital Medicine course, 2023- Biology, Genetics, Technology and BioInformatics. Includes lectures from Noam Shomron, Michal Rosen-Zvi, Eyal Zimlichman, Gila Tolub, Dana Bar-On, Yesha Sivan, Vladi Dvoryis, Varda Shalev, Avi Schroeder, Christian Tidano, Eyal Toledano.
Alagene BioFoundry: Releasing the Genie Out of the Bottle Levi Shapiro
Overview of Israel's leading BioFoundry, Alagene by Roni Cohen, CEO. Overview of Synthetic Biology- Taking biology into engineering mode. Using synthetic genes, to program cells to become factories to make devices, sensors, pharmaceuticals, renewable chemicals, fuels and food. Alagene has four partners with complementary expertise. Hylabs is an established and experienced, highly regulated service company. Reichman University is an academic partner with a commercialization mindset. The Israel Innovation Authority is the government and Aleph VC is an investment firm. Alagene is a home for innovation and R&D center in SynBio, serving as a one-stop—shop for knowledge, methods, and instrumentation to enable our customers in Israel and worldwide to get to their proof of concept. Alagene is anend to end Infrastructure supporting gene & host optimization in microbial systems. The infrastructure enables two Major Implementations- Biomanufacturing and Direct Microbial Application. One example is the development of a Dairy Milk Producing System, using Genetic Optimization and Process Optimization and Validation. Finally, Alagene shared the following recent project examples: Computational prediction for introducing new genes into microbes; Precision fermentation for yeast producing dairy proteins; Bio production of psychoactive / cannabinoid molecule in yeast; Bio production of growth factors for the cultured meat industry; Developing new inhouse tools to support strain optimization; Bio production of egg protein; Computational modeling of full metabolic network in Algae; Bio production of rare sugars with a low glycemic index.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...
Digitally powered participant-directed studies- Strategy for Decentralized Care. Adam Dicker, Jefferson Health, for mHealth Israel
1. Adam P. Dicker, MD, PhD, FASTRO, FASCO
Enterprise SVP, Professor & Chair-Radiation Oncology
Director, Jefferson Center for Digital Health & Data Science
2. Digitally powered
participant-directed studies
A Strategy for Decentralized Care
The Evolution of the Digital Patient Experience in Oncology
& opportunities for Human Augmented Intelligence and Touch
3. Outline
1. Precedent and example
2. Opportunities for Artificial Intelligence and/or Machine
Learning?
3. The human touch to augment technology
4. Challenges from a behavioral economics standpoint
5. Future directions
4. Evolving the Digital Patient Experience in Oncology
@APDicker
Telehealth 2.0
E Ray Dorsey, Eric J Topol, www.thelancet.com Vol 395 March 14, 2020
5.
6.
7. Dorsey, Kluger, Lipset, Annals of Neurology, 2020
“Digitally powered participant-directed studies are the
right direction and may be the new reality”
8. Evolving the Digital Patient Experience in Oncology
@APDicker
Patient Symptoms During Their Cancer Journey
Data taken from Mike’s patient journey at PM from 2017-2020. Used with permission from:
DR. ALEJANDRO (ALE) BERLIN, Princess Margaret Cancer Centre, University of Toronto
(physical, emotional, etc.)
9. Evolving the Digital Patient Experience in Oncology
@APDicker
Less than 1% of the time spent with provider -
How representative is our sampling?
Data taken from Mike’s patient journey at PM from 2017-2020. Used with permission from:
DR. ALEJANDRO (ALE) BERLIN, Princess Margaret Cancer Centre, University of Toronto
10. Evolving the Digital Patient Experience in Oncology
@APDicker
We must shift our focus to the ‘other’ 99% of time -
Patient centricity unrestricted by provider encounters.
Data taken from Mike’s patient journey at PM from 2017-2020. Used with permission from:
DR. ALEJANDRO (ALE) BERLIN, Princess Margaret Cancer Centre, University of Toronto
11. Evolving the Digital Patient Experience in Oncology
@APDicker
Patient Generated Health Data
20. Evolving the Digital Patient Experience in Oncology
@APDicker
TREATING THE WHOLE PERSON
Health coaching to address
social determinants to:
• Solve the 4000-hour problem
• Keep patients healthy at home
• Close care gaps between clinic visits
• Motivate healthy behavior change
to drive better outcomes
www.packhealth.com
21. Evolving the Digital Patient Experience in Oncology
Digital Health Possibilities for Community-Based Support
@Letitiathompson
Evidence suggests digital patient
support may help to:
• Address modifiable behaviors,
such as diet and exercise
• Reduce fatigue
• Improve BMI
• Improve health self-efficacy
For individuals with cancer, it has
demonstrated improved psychosocial
and behavioral health outcomes.
22. Evolving the Digital Patient Experience in Oncology
Insights from a Pilot of Digital Health Coaching
@Letitiathompson
Tumor-agnostic symptom support
program was offered to individuals across
the Southern United States:
• ACS partnered with Pack Health to
develop and deliver myJourney, a 3-
month digital health coaching
intervention
• To address barriers related to social
determinants, rideshare, financial
support services, and connecting
participants with community-based
resources were integrated into the
coaching
• ACS fostered enrollment to the
program through partnership with 70+
health systems in the states of
Louisiana, Alabama, Mississippi, Texas
& Oklahoma
1:1 health coaching
Multi-channel weekly touchpoints
Patient reported outcomes (PROs)
23. Evolving the Digital Patient Experience in Oncology
Pilot Study Data
@Letitiathompson
24. Outcomes of a Pilot Study
Exploring the Role of Digital
Health Coaching for Men with
Prostate Cancer
24
Handley NR, Wen KY, Gomaa S, Brassil K, Shimada A, Leiby B, Jackson L, McMorris
M, Calvaresi A, Dicker AP. A Pilot Feasibility Study of Digital Health Coaching for
Men With Prostate Cancer. JCO Oncol Pract. 2022
25.
26.
27. David Miller, MD, MS
Wake Forest University
"A Direct-to-Patient Digital Health
Intervention for Cancer Screening"
Kea Turner, PhD, MPH, MA
Moffitt Cancer Center
@TurnerKea
"Digital Health and
Malnutrition Management"
Erin Gillespie, MD
Memorial Sloan Kettering Cancer Center
@ErinGillespieMD
"Implementation Science and Care
Delivery Research: Opportunities in
Radiation Oncology"
Adam Dicker, MD, PhD, FASTRO, FASCO
Thomas Jefferson University
@APDicker
Sanjay Aneja, MD
Yale School of Medicine
@SanjayAnejaMD
Matthew F. Hudson, PhD, MPH
Prisma Health
Mary E. Cooley, PhD, RN, FAAN
Dana Farber/Harvard Cancer Center
Friday, April 15, 2022
12-1:30 pm EDT
NRGOncology NCORP Webinar
Implementation Science for Digital Health
Hosted by Digital Health & Cancer Care Delivery Research (CCDR) Committees
Program Speakers
Digital Health Co-Chairs
Register Today!
https://bit.ly/NRG-DH-CCDR-Webinar
CCDR Co-Chairs
Roberts AL, Fisher A, Smith L, Heinrich M, Potts HWW. Digital health behaviour change interventions targeting physical activity and diet in cancer survivors: a systematic review and meta-analysis. J Cancer Surviv. 2017;11(6):704-719.
77. Xu A, Wang Y, Wu X. Effectiveness of e-health based self-management to improve cancer-related fatigue, self-efficacy and quality of life in cancer patients: Systematic review and meta-analysis. J Adv Nurs. 2019;75(12):3434-3447.
78. Girault A, Ferrua M, Lalloue B, et al. Internet-based technologies to improve cancer care coordination: current use and attitudes among cancer patients. Eur J Cancer. 2015;51(4):551-557.
79. Madore S, Kilbourn K, Valverde P, Borrayo E, Raich P. Feasibility of a psychosocial and patient navigation intervention to improve access to treatment among underserved breast cancer patients. Support Care Cancer. 2014;22(8):2085-2093.
80. Green AC, Hayman LL, Cooley ME. Multiple health behavior change in adults with or at risk for cancer: a systematic review. Am J Health Behav. 2015;39(3):380-394.
81. Aapro M, Bossi P, Dasari A, et al. Digital health for optimal supportive care in oncology: benefits, limits, and future perspectives. Support Care Cancer. 2020;28(10):4589-4612.
82. Srivastava U, Burton S, Lewis MK, Patel D, Rasulnia M. Assessing the impact of a digital coaching program for patients with cancer. In: American Society of Clinical Oncology; 2018.
83. Banerjee R, Huang C-Y, Dunn L, et al. Feasibility of digital life coaching during stem cell transplantation for multiple myeloma. In: Wolters Kluwer Health; 2021.
84. Handley N, Wen K-Y, Gomaa S, Brassil KJ, Jackson L, Dicker AP. Exploring the role of digital health coaching for men with prostate cancer. In: Wolters Kluwer Health; 2021.
REMEMBER THAT THERE ARE SILOS INSIDE OF EACH OF THESE SILOS – THEY ARE THEMSELVES NOT MONOLITHS
EMPHASIS SHOULD BE THAT WE ARE NOT ONLY CREATING A BRIDGE TO OPEN COMMUNICATION.
WE ARE ALSO CREATING A NEW PERSON WHO HAS EXPERTISE IN ALL AREAS BROADLY – NOT ONLY JUST THESE 3.